NCT02896907View on ClinicalTrials.gov

Ascorbic Acid and Combination Chemotherapy in Treating Patients With Locally Advanced or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

October 18, 2016

Primary Completion Date

March 22, 2018

Study Completion Date

March 31, 2019

Conditions
Pancreatic AdenocarcinomaRecurrent Pancreatic CarcinomaStage III Pancreatic CancerStage IV Pancreatic CancerUnresectable Pancreatic Carcinoma
Interventions
DRUG

Oxaliplatin

Given IV

DRUG

Irinotecan Hydrochloride

Given IV

DRUG

Leucovorin Calcium

Given IV

DRUG

Fluorouracil

Given IV

DIETARY_SUPPLEMENT

Ascorbic Acid

Given IV

Trial Locations (1)

19107

Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia

All Listed Sponsors
lead

Sidney Kimmel Cancer Center at Thomas Jefferson University

OTHER

NCT02896907 - Ascorbic Acid and Combination Chemotherapy in Treating Patients With Locally Advanced or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery | Biotech Hunter | Biotech Hunter